RemeGen Co., Ltd. Announces Discloseable Transaction: Purchase of Wealth Management Products
Key Points and Summary
- RemeGen Co., Ltd., a biopharmaceutical company listed on both the Hong Kong Stock Exchange and Shanghai Stock Exchange, has approved the purchase of wealth management products using up to RMB2,500 million of idle self-owned funds.
- On May 14, 2026 and May 19, 2026, the Company signed six agreements with Huatai Securities Co., Ltd. (HTSC) to invest a total of RMB488 million in various wealth management products.
- The purchases constitute a “discloseable transaction” under Chapter 14 of the Hong Kong Listing Rules, triggered by one of the applicable percentage ratios exceeding 5% (but remaining below 25%). This mandates public reporting and announcement.
Detailed Transaction Overview
At its 36th board meeting on March 27, 2026, RemeGen approved a resolution to utilize idle self-owned funds for cash management purposes. The Company is allowed to invest up to RMB2,500 million in wealth management products. This move is aimed at increasing capital utilization efficiency and potentially generating higher returns than traditional bank deposits.
Agreements Signed with HTSC
- May 14, 2026:
- Agreement No. 1: RMB60 million
- Agreement No. 2: RMB75 million
- Agreement No. 3: RMB102 million
- Agreement No. 4: RMB216 million
- May 19, 2026:
- Agreement No. 5: RMB15 million
- Agreement No. 6: RMB20 million
Total investment across all agreements amounts to RMB488 million.
Product Details
- Agreement No. 5:
- Product Name: Huatai Ruyi Bao No.10 Collective Asset Management Plan
- Type: Fixed-income
- Risk Rating: Low-to-medium
- Principal: RMB15 million
- Term: 6 months, locked-in (no withdrawal allowed)
- Yield: Market-linked, performance subject to uncertainty
- Investment Scope: Commercial bank wealth management plans, securities company collective asset management plans, trust plans, bank deposits, money market funds, government bonds, bond reverse repurchase agreements, central bank bills, financial bonds, corporate bonds, bond funds, senior tranches of asset-backed securities, insurance asset management products, yield notes, OTC options, and other standardized assets permitted by the CSRC
- Right of Early Termination: Administrator may terminate early per agreement terms
- Agreement No. 6:
- Product Name: Xiamen Trust – Hongyun Xiangtai No.10 Asset Management Trust Product
- Product Code: ZXD202604210000005699
- Type: Fixed-Income Collective Fund Trust Plan
- Risk Rating: Medium
- Principal: RMB20 million
- Term: 36 months
- Yield: Market-linked, performance subject to uncertainty
- Investment Scope: Consumer loan assets via revolving purchase
- Right of Early Termination: Trustee may terminate early per agreement terms
Shareholder Information & Potential Price Sensitivity
- These investments are designed to maximize returns on idle funds while controlling risk. The products selected are considered to have low-to-medium risks and are expected to yield better returns than traditional bank time deposits.
- All transactions were conducted at arm’s length and with an independent financial institution. HTSC and its ultimate beneficial owners are not connected persons to RemeGen.
- Given the size of the aggregated transaction (RMB488 million), shareholders should note the potential impact on the Company’s liquidity, capital management, and future returns.
- The announcement complies with the Hong Kong Listing Rules, which require disclosure due to the scale of the transaction. This transparency is important for shareholders and may affect investor confidence and share price, especially if market conditions change or if risks materialize.
- The Company board considers the terms fair, reasonable, and in the best interest of shareholders.
Background on RemeGen and HTSC
- RemeGen is a leading biopharmaceutical company focused on innovative biologics for autoimmune, oncology, and ophthalmic diseases.
- HTSC is a major PRC securities company, listed in Shanghai and Hong Kong, providing wealth management, institutional services, investment management, and international business.
Board and Governance
- Chairman: Mr. Wang Weidong
- Board includes executive, non-executive, and independent directors.
Conclusion
The disclosed purchase of wealth management products represents a significant move by RemeGen to utilize idle funds efficiently, with the potential to improve returns and manage risk. Given the transaction’s size and compliance with disclosure rules, this announcement may be of interest to investors seeking insight into the Company’s financial strategy and risk appetite.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making any investment decisions related to RemeGen Co., Ltd. The information is based on publicly disclosed documents and may be subject to change.
RemeGen有限公司 – 購入理財產品之披露性交易 (廣東話版本)
重點摘要
- RemeGen有限公司（於香港及上海上市）批准以最多人民幣2,500百萬元自有閒置資金購買理財產品。
- 2026年5月14日及5月19日，公司與華泰證券（HTSC）簽訂六份協議，總共投資人民幣488百萬元於不同理財產品。
- 因涉及比例超過5%（但低於25%），此交易須按香港上市規則第14章作公開披露，屬披露性交易。
詳細交易內容
公司於2026年3月27日董事會會議批准利用閒置自有資金進行現金管理，最大投資額為人民幣2,500百萬元，以提升資金利用效率及獲取高於銀行定期存款的回報。
與華泰證券簽訂的協議
- 2026年5月14日：
- 協議一：人民幣60百萬元
- 協議二：人民幣75百萬元
- 協議三：人民幣102百萬元
- 協議四：人民幣216百萬元
- 2026年5月19日：
- 協議五：人民幣15百萬元
- 協議六：人民幣20百萬元
六份協議總投資額為人民幣488百萬元。
產品細節
- 協議五：
- 產品名稱：華泰如意寶10號集合資產管理計劃
- 類型：固定收益
- 風險評級：低至中風險
- 本金：人民幣15百萬元
- 期限：6個月，期間不可贖回
- 預期年化收益：隨市場波動，具不確定性
- 投資範圍：標準化資產，包括銀行理財、證券資管計劃、信託計劃、銀行存款、貨幣基金、國債、回購、央票、金融債、公司債、債券基金、資產證券化高級分層、保險資管產品、收益票據、場外期權等
- 提前終止權：管理人可按協議終止
- 協議六：
- 產品名稱：廈門信託 – 鴻運翔泰10號資產管理信託產品
- 產品編號：ZXD202604210000005699
- 類型：固定收益集合資金信託計劃
- 風險評級：中風險
- 本金：人民幣20百萬元
- 期限：預計36個月
- 預期年化收益：隨市場波動，具不確定性
- 投資範圍：以循環購買方式投資消費貸款資產
- 提前終止權：受託人可按協議終止
股東須知及潛在影響
- 此次投資旨在於控制風險前提下，提升閒置資金回報。所選產品屬低至中風險，預期收益高於銀行定期。
- 交易與獨立金融機構華泰證券進行，對方及其實益擁有人與公司無關。
- 鑑於交易規模（人民幣488百萬元），股東須注意對公司流動性、資金管理及未來收益的潛在影響。
- 公告依規公開披露，透明度提升或影響市場信心及股價，尤其市場波動或風險兌現時。
- 董事認為交易條款公平合理，符合公司及股東整體利益。
公司及合作方簡介
- RemeGen為領先的創新生物藥企，重點於自身免疫、腫瘤及眼科疾病。
- 華泰證券為中國主要證券公司，於上海及香港上市，提供財富管理、機構服務、投資管理及國際業務。
董事會及管治
- 主席：王維東先生
- 董事會包括執行、非執行及獨立董事。
總結
此次理財產品購買披露，顯示RemeGen靈活運用閒置資金、提升資金效率及管理風險。交易規模大，按規披露，有望為投資者提供公司財務策略及風險偏好之重要資訊，或對股價構成影響。
免責聲明
本文章僅供資訊參考，並不構成投資建議。投資者應自行調查並諮詢專業財務顧問，方作任何與RemeGen有限公司相關的投資決策。資料來自公開披露文件，或會有所變動。
